Go to content
UR Home

Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group

Stupp, R. ; Tosoni, A. ; Bromberg, J. E. C. ; Hau, Peter ; Campone, M. ; Gijtenbeek, J. ; Frenay, M. ; Breimer, L. ; Wiesinger, H. ; Allgeier, A. ; van den Bent, M. J. ; Bogdahn, Ulrich ; van der Graaf, W. ; Yun, H. J. ; Gorlia, T. ; Lacombe, D. ; Brandes, A. A.



Abstract

No evidence of relevant clinical antitumor activity against recurrent glioblastoma could be detected. Sagopilone was well tolerated, and moderate-to-severe peripheral neuropathy was observed in despite prolonged administration.


Owner only: item control page
  1. Homepage UR

University Library

Publication Server

Contact:

Publishing: oa@ur.de

Dissertations: dissertationen@ur.de

Research data: daten@ur.de

Contact persons